RecruitingNCT03449706

Accurate Staging of Immuno-virological Dynamics During Acute HIV Infection


Sponsor

University Hospital, Ghent

Enrollment

70 participants

Start Date

Sep 1, 2017

Study Type

OBSERVATIONAL

Conditions

Summary

In this prospective longitudinal study we aim to assess how immunologic and viral aspects of the human immunodeficiency virus (HIV) viral reservoir, established during early HIV infection and responsible for viral rebound at treatment interruption, evolve in individuals who start combination anti-retroviral therapy (cART) during acute seroconversion. Recently infected patients will be selected based on Fiebig staging for an in depth sampling protocol at different timepoints during a 2 year follow up period. Colonbiopsies, lymphnode resection, lumbar puncture, leucapheresis and repeated peripheral venous blood-draws will be performed. Immunological, virological and genome expression analysis will be performed on the gathered samples.


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study is carefully characterizing the very early stages of HIV infection — the first days and weeks after someone is infected — by testing and monitoring people who were recently exposed or are showing early symptoms, to better understand how the immune system responds. **You may be eligible if...** - You have been recently diagnosed with a new (acute) HIV-1 infection - You show signs of early HIV infection: either early symptoms, an incomplete Western blot test result, or a recent negative HIV test (within 6 months) - OR you had a known risk exposure within the past 3 months with signs pointing to early infection - You are able and willing to provide informed consent - You are able to attend regular follow-up visits (or at least a partial schedule) **You may NOT be eligible if...** - You do not have documented recent HIV-1 infection - You are unwilling or unable to provide informed consent - You cannot attend the scheduled visits Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGEarly combination anti-retroviral treatment

Patients are started on treatment to supress the HIV virus in the phase of acute seroconversion.


Locations(1)

UZ Gent

Ghent, Oost-Vlaanderen, Belgium

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03449706


Related Trials